Intellectual Property
Total 67 Posts
USTR Releases 2023 Special 301 Report on Intellectual Property Protection and Enforcement
Earlier this week, the Office of the United States Trade Representative (USTR) released its 2023 Special 301 Report "on the adequacy and effectiveness of U.S. trading partners’ protection and enforcement of intellectual property (IP) rights," repeating many of its long-standing complaints about Chinese policies and practices in
WTO Panel Composed in EU Complaint about Chinese Anti-Suit Injunctions
The WTO announced today that a panel had been composed to hear an EU complaint related to China's enforcement of intellectual property rights.
Debating China's Courts and Intellectual Property
A recent Wall Street Journal article on China's use of courts in the area of intellectual property protection prompted a critical response from a leading U.S. expert on Chinese intellectual property law.
U.S. Congressional Committee Holds Hearing on Intellectual Property and Strategic Competition with China
A House of Representatives Subcommittee held a hearing yesterday on "Intellectual Property and Strategic Competition with China," with members of the Subcommittee and expert witnesses discussing a number of issues related to Chinese intellectual property protection, including the patent system and innovation in China.
USTR Issues 2023 Report on Notorious Markets for Counterfeiting and Piracy
Earlier this week, the Office of the U.S. Trade Representative issued its 2022 Review of Notorious Markets for Counterfeiting and Piracy (Notorious Markets List, or NML), which "highlights prominent and illustrative examples of online and physical markets that reportedly engage in, facilitate, turn a blind eye to, or
WTO Panels Established To Hear EU Complaints against China
At Friday's meeting of the WTO's Dispute Settlement Body (DSB), panels were established in two complaints brought against China by the EU, related to allegations about China's trade restrictions imposed on Lithuania and about restrictions on EU companies going to a foreign court to
Paxlovid in China: A Debate on Compulsory Licensing
After the failure by Pfizer and the Chinese government to reach an agreement on including COVID medicine Paxlovid in the state health insurance plan, there are some discussions in China on whether compulsory licensing is justified as cases are surging in the nation.